Dr. Arie Belldegrun has had a distinguished career as a visionary surgeon, scientist and life sciences entrepreneur. Arie co-founded and serves as Executive Chairman of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapy. Arie also founded Kite Pharma, a biopharmaceutical company engaged in the development of innovation cancer immunotherapies, and served as Kite’s Chairman, President and CEO until its acquisition by Gilead Sciences in 2017. Arie was closely involved with the founding and advancement of biopharmaceutical companies Cougar Biotechnology, Cell Design Labs, and Agensys.
He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and Bellco Capital, and as co-Chairman of Breakthrough Properties. He is a Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston, San Francisco and Los Angeles.
Arie is also Professor of Urology, Director of the Institute of Urologic Oncology, and holds the Roy and Carol Doumani Chair in Urologic Oncology at the David Geffen School of Medicine at UCLA. Arie completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate fellowship at the Weizmann Institute of Science and his residency in Urological Surgery at Harvard Medical School.
“Throw them into the pool on day 1: it’ll teach them that – in life – you either sink or swim!“